ArticleMolecular pharmacology2025
The peroxisome proliferator-activated receptor α/β/γ agonist NCPC-626 from microbial metabolites alleviates metabolic dysfunction-associated steatohepatitis in mice.
Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Decoding the heterogeneity of liver-resident macrophages in chronic liver diseases: therapeutic responses to immunomodulatory strategies.Frontiers in pharmacology · 2025Review
- Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by steatosis, inflammatory responses, and fibrosis. Peroxisome proliferator-activated receptors (PPARs), master regulators of glucolipid homeostasis and inflammatory pathways, have emerged as promising therapeutic targets for MASH. PPAR agonists have demonstrated therapeutic potential in MASH by ameliorating hepatic lipid deposition, normalizing dyslipidemia, enhancing insulin sensitivity, and suppressing proinflammatory signaling. In this study, we reported that NCPC-626, a natural fungal metabolite, was discovered as a novel potent pan-PPAR agonist through high-throughput screening. In an in vitro model of MASH, NCPC-626 inhibited lipid accumulation, fibrosis, and inflammation. Moreover, NCPC-626 treatment reduced body weight, liver triglyceride levels, and improved glucose tolerance in db/db mice by regulating glucolipid metabolism. Additionally, NCPC-626 exhibited preventive and therapeutic effects against fibrosis in a CCl
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.